Lumacaftor | VX-809;VRT 826809;Orkambi;Lumacaftor | CFTR

首页 / 抑制剂/激动剂 / 膜转运蛋白 / CFTR / Lumacaftor

鲁玛卡托 /Lumacaftor {[allProObj[0].p_purity_real_show]}

货号：A121674 同义名： VX-809;VRT 826809

Lumacaftor (VX-809; VRT 826809) 是一种CFTR调节剂，可纠正CFTR蛋白的折叠和运输。

Lumacaftor 化学结构
CAS号：936727-05-8

Lumacaftor 3D分子结构
CAS号：936727-05-8

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Lumacaftor 纯度/质量文件产品仅供科研

货号：A121674 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell Host Microbe, 2024. Ambeed. [ A163338 ]; • Cancer Res., 2024. Ambeed. [ A295334 ]; • J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]; • J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]; • JBC, 2024, 107935. Ambeed. [ A194396 ]; 更多 >

CFTR 亚型比较

产品名称	CFTR ↓ ↑	纯度
Ataluren	✔	98%
Lumacaftor	++++ F508del-CFTR, EC50: 0.1 μM	98%
CFTR(inh)-172	+++ CFTR, Ki: 300 nM	99%+
GlyH-101	+ CFTR, Ki: 4.3 μM	99%+
IOWH-032	++ CFTR, IC50: 1.01 μM	99%+
Tezacaftor	✔	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Lumacaftor 生物活性

靶点	CFTR F508del-CFTR, EC50:0.1 μM
描述	Cystic fibrosis (CF) is a genetic disorder with the loss of chloride transport due to the defects in CF transmembrane conductance regulator (CFTR) protein. VX-809 is a CFTP corrector that partially increases the delivery of CFTR to cell surface, thereby restoring the function of chloride transportation. It improved the maturation of F508del-CFTR, the most common CFTR mutation, in FRT cells with an EC50 value at 0.1 μM; and increased F508del-CFTR-mediated chloride transport with an EC50 at 0.5 μM. Data from F508del-HEK293 cells showed that incubation with 3 μM VX-809 for 24 hours increased F508del-CFTR exit from the endoplasmic reticulum by 6 folds compared with control cells. Also, cultured F508del-HBE cells treated with 3 μM VX-809 for 48 hours showed 14% higher maximal level of chloride transport compared to normal HBE cells^[5]. In a human lung epithelium-derived cell line that was transfected with horseradish peroxidase (HRP)-tagged CFTR (F508-HRP CFBE41o^-), cells treated with 2 μM VX-809 at 37C for 24 hours showed 4-fold HRP luminescence signal increase compared to DMSO-treated cells. Similar result was also found in R1070W-HRP CFBE41o^- cells with 2.5-fold signal increase after VX-809 treatment at the concentration of 2 μM^[6]. A phase 2 study in homozygous CF patients reported that daily intake of 100 and 200 mg VX-809 for 28 days significantly decreased their elevated sweat chloride values^[7].
作用机制	VX-809 suppresses the folding defects of transmembrane conductance regulator (CFTR) protein by stabilizing an N-terminal domain in the CFTR that contains membrane-spanning domain 1^[8].

Lumacaftor 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
human CFBE41o cells		Function assay		Corrector activity at CFTR F508del mutant (unknown origin) expressed in human CFBE41o cells assessed as increase in fully glycosylated protein by western blot analysis	26041577

Lumacaftor 动物研究

Dose

Mice: 1.5 mg/kg^[3] (i.v.) Rat: 1 mg/kg^[4] (p.o.)， 1 mg/kg - 600 mg/kg^[3] (p.o.), 1 mg/kg - 5 mg/kg^[3] (i.v.)

Administration

i.v., p.o.

Pharmacokinetics

Animal	Rats^[3]
Dose	30 mg/kg (p.o.) 3 mg/kg (i.v.)
Administration	p.o. i.v.
F	69.7% (p.o.)
T_1/2	6.46 h (p.o.) 8.62 h (i.v.)
T_max	2.0 h (p.o.) 0.083 h (i.v.)
C_max	66200 ng/g (p.o.) 24600 ng/g (i.v.)
AUC_0→∞	410000 ng·h/g (p.o.) 58900 ng·h/g (i.v.)
AUC_0→t	410000 ng·h/g (p.o.) 58900 ng·h/g (i.v.)

Lumacaftor 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03474042	Cystic Fibrosis	Phase 2	Completed	-	Germany ... 展开 >> Study Site II Berlin, Germany Study Site X Dresden, Germany Study Site III Essen, Germany Study Site IV Frankfurt, Germany Study Site I Heidelberg, Germany Study Site V Köln, Germany Study Site VI München, Germany Study Site IX Stuttgart, Germany Study Site VIII Tübingen, Germany 收起 <<
NCT02821130	-		Active, not recruiting	December 2019	Canada, British Columbia ... 展开 >> UBC James Hogg Research Centre, St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z1Y6 收起 <<
NCT02965326	Cystic Fibrosis	Not Applicable	Recruiting	October 2020	France ... 展开 >> Necker Hospital Recruiting Paris, France, 75014 Contact: SERMET Isabelle, Professor 01 44 49 48 87 isabelle.sermet@nck.aphp.fr Principal Investigator: SERMET Isabelle, Professor 收起 <<

Lumacaftor 参考文献

[1]lumacaftor

[2]Van Goor F, Hadida S, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8.

[3]108(46):18843-8.

[4]86(1):42-51.

[5]Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8.

[6]Phuan PW, Veit G, Tan J, Roldan A, Finkbeiner WE, Lukacs GL, Verkman AS. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol. 2014 Jul;86(1):42-51.

Lumacaftor 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.21mL

0.44mL

0.22mL

11.05mL

2.21mL

1.11mL

22.10mL

4.42mL

2.21mL

Lumacaftor 技术信息

CAS号	936727-05-8
分子式	C₂₄H₁₈F₂N₂O₅
分子量	452.41

别名	VX-809;VRT 826809;Orkambi;Lumacaftor
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Room temperature

溶解度

DMSO: 25 mg/mL(55.26 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 4 mg/mL clear

PO 0.5% CMC-Na 40 mg/mL suspension

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03474042	Cystic Fibrosis	Phase 2	Completed	-	Germany ... 展开 >> Study Site II Berlin, Germany Study Site X Dresden, Germany Study Site III Essen, Germany Study Site IV Frankfurt, Germany Study Site I Heidelberg, Germany Study Site V Köln, Germany Study Site VI München, Germany Study Site IX Stuttgart, Germany Study Site VIII Tübingen, Germany 收起 <<
NCT02821130	-		Active, not recruiting	December 2019	Canada, British Columbia ... 展开 >> UBC James Hogg Research Centre, St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z1Y6 收起 <<
NCT02965326	Cystic Fibrosis	Not Applicable	Recruiting	October 2020	France ... 展开 >> Necker Hospital Recruiting Paris, France, 75014 Contact: SERMET Isabelle, Professor 01 44 49 48 87 isabelle.sermet@nck.aphp.fr Principal Investigator: SERMET Isabelle, Professor 收起 <<
NCT02275936	Cystic Fibrosis	Phase 1	Completed	-	United States, Alabama ... 展开 >> University of Alabama @ Birmingham Birmingham, Alabama, United States, 35294 United States, California Stanford University Palo Alto, California, United States, 94304 United States, Colorado Children's CO Aurora, Colorado, United States, 80045 National Jewish Health Denver, Colorado, United States, 80206 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Iowa University of Iowa Children's Hospital Iowa City, Iowa, United States, 52242 United States, Maryland Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, Massachusetts Boston Children's Hospital Boston, Massachusetts, United States, 02115 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, Missouri Washington University St. Louis, Missouri, United States, 63110 United States, New York Columbia University New York, New York, United States, 10032 The New York Presbyterian Hospital, Columbia University Medical Center New York, New York, United States, 10032 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Ohio Cincinnati Children's Hospital Cincinnati, Ohio, United States, 45229 Rainbow Babies and Children's Hospital - Case Medical Center Cleveland, Ohio, United States, 44106 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 收起 <<
NCT02310789	-		Completed	-	-
NCT03140527	Healthy Volunteer - Complete ... 展开 >> Cystic Fibrosis 收起 <<	Phase 1	Recruiting	August 2018	-
NCT02709109	Cystic Fibrosis	Phase 2	Completed	-	-
NCT02310789	Cystic Fibrosis	Not Applicable	Completed	-	United States, California ... 展开 >> Stanford Hospital and Clinics Stanford, California, United States, 94305 收起 <<
NCT03445793	-		Recruiting	December 31, 2019	United States, Colorado ... 展开 >> National Jewish Heatlh Recruiting Denver, Colorado, United States, 80206 Contact: Terri Herrud, BS 303-398-1453 herrudt@njhealth.org 收起 <<
NCT02589236	Cystic Fibrosis	Phase 2	Completed	-	-
NCT03061331	Cystic Fibrosis	Phase 2	Completed	-	Netherlands ... 展开 >> HagaZiekenhuis Den Haag, Netherlands University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis Heidelberglaan, Netherlands 收起 <<
NCT03150719	Cystic Fibrosis	Phase 3	Completed	-	-
NCT03061331	-		Completed	-	-
NCT03125395	Cystic Fibrosis	Phase 3	Active, not recruiting	July 26, 2019	-
NCT03506061	Cystic Fibrosis	Phase 2	Not yet recruiting	May 2023	United States, Alabama ... 展开 >> University of Alabama Cystic Fibrosis Research Center Not yet recruiting Birmingham, Alabama, United States, 35233 Contact: George Soloman, MD 205-975-9776 msolomon@uab.edu United States, Georgia Emory Children's Center Not yet recruiting Atlanta, Georgia, United States, 30322 Contact: Eric Sorscher, MD 205-612-1327 esorscher@emory.edu 收起 <<
NCT02875366	Cystic Fibrosis	Phase 4	Completed	-	Australia, Victoria ... 展开 >> Melbourne, Victoria, Australia Parkville, Victoria, Australia Australia Adelaide, Australia Camperdown, Australia Clayton, Australia Nedlands, Australia New Lambton Heights, Australia Randwick, Australia South Brisbane, Australia Subiaco, Australia Westmead, Australia United Kingdom Edinburgh, United Kingdom 收起 <<
NCT03625466	Cystic Fibrosis	Phase 2	Recruiting	May 2021	Germany ... 展开 >> Charite Paediatric Pulmonology Department Recruiting Berlin, Germany Justus-Leibig-Universitat Zentrum fur Kinderheilkunde und Jugendmedizin Recruiting Giessen, Germany Hannover Medical School Recruiting Hannover, Germany Heidelberg Cystic Fibrosis Center Recruiting Heidelberg, Germany Universitatsklinikum Schleswig-Holstein, Klinik für Kinder- und Jugendmedizin Recruiting Lubeck, Germany 收起 <<
NCT01931839	Cystic Fibrosis, Homozygous or... 展开 >> Heterozygous for the F508del-CFTR Mutation 收起 <<	Phase 3	Completed	-	-
NCT01888393	Hepatic Impairment ... 展开 >> Healthy 收起 <<	Phase 1	Completed	-	Czech Republic ... 展开 >> Praha, Czech Republic Slovakia Bratislava, Slovakia 收起 <<
NCT03565692	-		Not yet recruiting	March 1, 2020	France ... 展开 >> CHU de Bordeaux - CRCM Not yet recruiting Bordeaux, France, 33000 Contact: Mickael FAYON, MD,PhD mickael.fayon@chu-bordeaux.fr Principal Investigator: Mickael FAYON, MD,PhD Sub-Investigator: Patrick BERGER, MD,PhD Sub-Investigator: Raphael ENAUD, MD Centre Hospitalier Universitaire Grenoble Alpes Not yet recruiting Grenoble, France, 38000 Contact: Catherine Llerena, MD CLlerena@chu-grenoble.fr Principal Investigator: Catherine Llerena, MD Sub-Investigator: Boubou Camara, MD CHRU de Lille Not yet recruiting Lille, France, 69000 Contact: Nathalie Wizla, MD nathalie.wizla@chru-lille.fr Principal Investigator: Nathalie Wizla, MD Sub-Investigator: Anne Prévotat, MD Hospices Civils de Lyon Not yet recruiting Lyon, France, 69000 Contact: Philippe Reix, MD philippe.reix@chu-lyon.fr Principal Investigator: Philippe Reix, MD Assistance publique Hôpitaux Marseille Not yet recruiting Marseille, France, 13000 Contact: Jean Christophe Dubus, MD,PhD JeanChristophe.DUBUS@ap-hm.fr Principal Investigator: Jean Christophe Dubus, MD,PhD Assistance Publique Hôpitaux de paris Not yet recruiting Paris, France, 75000 Contact: Harriet Corvol, MD,PhD harriet.corvol@aphp.fr Principal Investigator: Harriet Corvol, MD,PhD Sub-Investigator: Pierre-Regis BURGEL, MD Sub-Investigator: Isabelle Sermet-Gaudelus, MD,PhD Sub-Investigator: Michèle Gérardin Gérardin, MD Hôpital FOCH Not yet recruiting Suresnes, France, 92150 Contact: Dominique Grenet, MD d.grenet@hopital-foch.org Principal Investigator: Dominique Grenet, MD CHU de Toulouse Not yet recruiting Toulouse, France, 31000 Contact: Marlène Murris-Espin, MD murris.m@chu-toulouse.fr Contact: Murris-Espin Principal Investigator: Marlène Murris-Espin, MD 收起 <<
NCT02823470	Cystic Fibrosis	Phase 4	Terminated(Study terminated ea... 展开 >>rly due to slow recruitment of patients.) 收起 <<	-	United States, Connecticut ... 展开 >> Hartford, Connecticut, United States United States, District of Columbia Washington, District of Columbia, United States United States, Florida Orlando, Florida, United States United States, Georgia Atlanta, Georgia, United States United States, Mississippi Jackson, Mississippi, United States United States, New Mexico Albuquerque, New Mexico, United States United States, South Carolina Columbia, South Carolina, United States Canada, Alberta Edmonton, Alberta, Canada Canada, British Columbia Victoria, British Columbia, Canada Canada, New Brunswick Saint John, New Brunswick, Canada Canada Quebec, Canada 收起 <<
NCT02797132	Cystic Fibrosis	Phase 3	Completed	-	-
NCT02544451	Cystic Fibrosis	Phase 3	Active, not recruiting	November 2019	-
NCT01931839	-		Completed	-	-
NCT02823470	-		Terminated(Study terminated ea... 展开 >>rly due to slow recruitment of patients.) 收起 <<	-	-
NCT01910415	Cystic Fibrosis	Phase 1	Completed	-	Netherlands ... 展开 >> Zuidlaren, Netherlands 收起 <<
NCT03601637	Cystic Fibrosis	Phase 3	Recruiting	September 2020	United States, Alabama ... 展开 >> University of Alabama at Birmingham Recruiting Birmingham, Alabama, United States, 35294 United States, Arkansas Arkansas Children's Hospital Recruiting Little Rock, Arkansas, United States, 72202 United States, Illinois Ann & Robert Lurie Children's Hospital of Chicago Recruiting Chicago, Illinois, United States, 60611 United States, Indiana Riley Hospital for Children at Indiana University Health Recruiting Indianapolis, Indiana, United States, 46202 United States, Massachusetts Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02115 United States, Minnesota Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota Recruiting Minneapolis, Minnesota, United States, 55404 United States, Missouri The Children's Mercy Hospital Recruiting Kansas City, Missouri, United States, 64108 United States, New York Albany Medical College Recruiting Albany, New York, United States, 12208 United States, Pennsylvania Children's Hospital of Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19104 United States, Texas Cook Children's Medical Center Recruiting Fort Worth, Texas, United States, 76104 United States, Utah University of Utah / Primary Children's Medical Center Recruiting Salt Lake City, Utah, United States, 84132 United States, Washington Seattle Children's Hospital Recruiting Seattle, Washington, United States, 98105 United States, Wisconsin University of Wisconsin Hospital and Clinics Recruiting Madison, Wisconsin, United States, 53792 Canada British Columbia's Children's Hospital Recruiting Vancouver, Canada 收起 <<
NCT01807949	Cystic Fibrosis, Homozygous fo... 展开 >>r the F508del CFTR Mutation 收起 <<	Phase 3	Completed	-	-
NCT02858843	Cystic Fibrosis ... 展开 >> Diabetes 收起 <<	Not Applicable	Terminated(We were unable to e... 展开 >>nroll eligible subjects for the study.) 收起 <<	-	-
NCT01807923	Cystic Fibrosis, Homozygous fo... 展开 >>r the F508del CFTR Mutation 收起 <<	Phase 3	Completed	-	-
NCT02797132	-		Completed	-	-
NCT02514473	Cystic Fibrosis	Phase 3	Completed	-	-
NCT03512119	-		Recruiting	October 10, 2018	France ... 展开 >> Hôpitaux Universitaires de Strasbourg Recruiting Strasbourg, Alsace, France, 67000 Contact: Laurence KESSLER Principal Investigator: Laurence KESSLER, MD Centre Hospitalier Universitaire d'Angers Recruiting Angers, France, 49033 Contact: Françoise TROUSSIER Principal Investigator: Françoise TROUSSIER Hôpital Renée Sabran Recruiting Giens, France, 83406 Contact: Laurent MELY Principal Investigator: Laurent MELY Centre Hospitalier Lyon Sud Recruiting Lyon, France, 69000 Contact: Isabelle DURIEU Principal Investigator: Isabelle DURIEU Hôpital NORD - Assistance Publique Hôpitaux de Marseille Recruiting Marseille, France, 13385 Contact: Bérengère COLTEY Principal Investigator: Bérengère COLTEY Hôpital Arnaud de Villeneuve Recruiting Montpellier, France, 34295 Contact: Raphael CHIRON Principal Investigator: Raphael CHIRON Hôpital Robert Debré Recruiting Paris, France, 75019 Contact: Michèle GERARDIN Principal Investigator: Michèle GERARDIN American Memorial Hospital Recruiting Reims, France, 51092 Contact: Michel ABLEY Principal Investigator: Michel ABELY Clinique "Mucoviscidose" Presqu'île de Perharidy Recruiting Roscoff, France, 29684 Contact: Gilles RAULT Principal Investigator: Gilles RAULT Hôpital Charles Nicolle Recruiting Rouen, France, 76031 Contact: Stéphane DOMINIQUE Principal Investigator: Stéphane DOMINIQUE Hôpital FOCH Recruiting Suresnes, France, 92151 Contact: Florence BOUILLOUD Principal Investigator: Florence BOUILLOUD Hôpital Bretonneau - CHRU de Tours Recruiting Tours, France, 37044 Contact: Julie MANKIKIAN Principal Investigator: Julie MANKIKIAN Hôpital de Clocheville - CHRU de Tours Recruiting Tours, France, 37044 Contact: Laure COSSON Principal Investigator: Laure COSSON 收起 <<
NCT01807949	-		Completed	-	-
NCT03475381	-		Active, not recruiting	June 30, 2018	France ... 展开 >> Adult CF center, Service de Pneumologie, Cochin Hospital Paris, France, 75006 收起 <<
NCT02390219	Cystic Fibrosis ... 展开 >> Advanced Lung Disease 收起 <<	Phase 3	Completed	-	United States, Colorado ... 展开 >> Denver, Colorado, United States United States, Florida Tampa, Florida, United States United States, Illinois Chicago, Illinois, United States United States, Missouri Saint Louis, Missouri, United States United States, Pennsylvania Pittsburgh, Pennsylvania, United States United States, Texas Houston, Texas, United States 收起 <<
NCT01768663	Cystic Fibrosis	Phase 1	Completed	-	United States, Indiana ... 展开 >> Evansville, Indiana, United States 收起 <<
NCT02390219	-		Completed	-	-
NCT01807923	-		Completed	-	-
NCT02514473	-		Completed	-	-
NCT01225211	Cystic Fibrosis	Phase 2	Completed	-	-
NCT01899105	Cystic Fibrosis	Phase 1	Completed	-	United States, Florida ... 展开 >> Daytona, Florida, United States 收起 <<
NCT02653027	Diabetes Cyst... 展开 >>ic Fibrosis 收起 <<	Not Applicable	Withdrawn(We couldn't find any... 展开 >> eligible subjects for the study because most of the study population had already started on the combination therapy.) 收起 <<	-	-
NCT01897233	Cystic Fibrosis	Phase 3	Completed	-	-
NCT02807415	-		Recruiting	June 2019	Germany ... 展开 >> Justus-Liebig-University Recruiting Gießen, Germany, 35385 Contact: Lutz Nährlich, MD 004964198557620 lutz.naehrlich@paediat.med.uni-giessen.de Contact: Claudia Rückes-Nilges, Dipl-Biol 004964198556945 claudia.rueckes-nilges@paediat.med.uni-giessen.de Principal Investigator: Lutz Nährlich, MD Sub-Investigator: Stefan Kuhnert, MD Hannover Medical School Recruiting Hannover, Germany, 30625 Contact: Burkhard Tümmler, MD PhD 00495115322920 tuemmler.burkhard@mh-hannover.de Contact: Christian Dopfer, MD 00495115326111 dopfer.christian@mh-hannover.de Principal Investigator: Burkhard Tümmler, MD PhD Sub-Investigator: Christian Dopfer, MD University of Heidelberg Recruiting Heidelberg, Germany, 69120 Contact: Marcus Mall, MD 00496221564502 Marcus.Mall@med.uni-heidelberg.de Contact: Simon Gräber, MD 004962215638926 Simon.Graeber@med.uni-heidelberg.de Principal Investigator: Marcus Mall, MD Sub-Investigator: Simon Gräber, MD Sub-Investigator: Susanne Dittrich, MD 收起 <<
NCT00865904	Cystic Fibrosis	Phase 2	Completed	-	-
NCT01897233	-		Completed	-	-
NCT01216046	Cystic Fibrosis	Phase 1	Completed	-	United States, Kansas ... 展开 >> PRA Lenexa, Kansas, United States, 66219 收起 <<
NCT01225211	-		Completed	-	-
NCT00865904	-		Completed	-	-
NCT00966602	Cystic Fibrosis	Phase 1	Completed	-	Netherlands ... 展开 >> Zuidlaren, Netherlands 收起 <<

鲁玛卡托 /Lumacaftor {[allProObj[0].p_purity_real_show]}

Lumacaftor 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Lumacaftor 质控信息

Lumacaftor 生物活性

Lumacaftor 细胞研究

Lumacaftor 动物研究

Lumacaftor 临床研究

Lumacaftor 参考文献

Lumacaftor 实验方案

Lumacaftor 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

鲁玛卡托 /Lumacaftor {[allProObj[0].p_purity_real_show]}

Lumacaftor 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Lumacaftor 质控信息

Lumacaftor 生物活性

Lumacaftor 细胞研究

Lumacaftor 动物研究

Lumacaftor 临床研究

Lumacaftor 参考文献

Lumacaftor 实验方案

Lumacaftor 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Lumacaftor 纯度/质量文件产品仅供科研